[go: up one dir, main page]

KR930004262A - 메타노안트라센 화합물 - Google Patents

메타노안트라센 화합물 Download PDF

Info

Publication number
KR930004262A
KR930004262A KR1019920014726A KR920014726A KR930004262A KR 930004262 A KR930004262 A KR 930004262A KR 1019920014726 A KR1019920014726 A KR 1019920014726A KR 920014726 A KR920014726 A KR 920014726A KR 930004262 A KR930004262 A KR 930004262A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
formula
hydrogen
alkoxy
Prior art date
Application number
KR1019920014726A
Other languages
English (en)
Other versions
KR100245955B1 (ko
Inventor
톰즈 제이컵스 로버트
테디어스 클리마스 마이클
존 오마크트 사이러스
오널 터프코 마크
Original Assignee
수잔 제인 젠틀
임페리얼 케미칼 인더스트리스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수잔 제인 젠틀, 임페리얼 케미칼 인더스트리스 피엘씨 filed Critical 수잔 제인 젠틀
Publication of KR930004262A publication Critical patent/KR930004262A/ko
Application granted granted Critical
Publication of KR100245955B1 publication Critical patent/KR100245955B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음.

Description

메타노안트라센 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 일반식(Ⅰ)의 화합물 또는 그것의 약학적으로 허용가능한 염.
    상기 식에서 X와 Y는 각각 수소, 할로, 및 (1-6C)알콕시중에서 선택되고, R1은 (A) (1-6C)알킬, (B) 각각 (1-6C)알킬, (1-6C)알콕시, 히드록시, 할로, 시아노, 니트로, 페닐, 벤질옥시, 벤조일, 트리플루오로메틸, 일반식 SO2NRaRb로 표시되는 아미노설포닐, 및 일반식 CONRcRd로 표시되는 아미노카르보닐(이때 Ra, Rb, Rc및 Rd는 각각 수소, 2-피롤리디닐, 및 (1-6C)알킬중에서 선택되거나, 또는 Ra와 Rb, 및 Rc와 Rd는 이들이 각각 결합하고 있는 질소 원자와 함께 5-원소 또는 6-원소로 구성된 헤테로사이클계 링을 형성하며, 상기 질소 원자는 유일한 이종 원자이다), 및 RhRiN(1-3C)알킬(이때 Rh와 Ri는 각각 수소 및 (1-3C)알킬중에서 선택된다)로 이루어진 군중에서 선택된 0-3개의 치환기를 가질 수 있는 페닐 및 나트틸, (C) 페닐(1-3C)알킬 및 나프틸(1-3C)알킬(이때 페닐 및 나프틸기는 상기 (B)에 주어진 페닐 및 나프틸 치환기 중에서 선택된 0-3개의 치환기를 가질 수 있다), (D) 질소, 산소, 및 황중에서 선택된 1-3개의 이종 원자를 함유하고, (1-6C)알킬, 히드록시, 트리플루오로메틸기를 가질 수 있는 (1-6C)알콕시, (1-6C)알콕시카르보닐, (1-6C)히드록시알킬, 벤질옥시, 할로, (1-3C) 알킬아미노카르보닐(1-3C)알킬, 상기 (B)에서 정의한 바와 같은 아미노카르보닐, ReS(O)n, RfNH 및 RgS중에서 선택된 0-2개의 치환기를 가질 수 있는, 5-원소 및 6-원소로 구성된 헤테로아릴링, 또는 이것의 벤즈유도체(이때 Re와 Rf는 각각 수소 및 (1-6C)알킬중에서 선택되고 n은 0, 1 또는 2이며, Rg는 (1-3C)알킬카르보닐아미노페닐 및 디(1-3C)알킬아미노 (1-6C)알킬중에서 선택된다), (E) 헤테로아릴기가 상기 (D)에서 정의한 바와 같은 5-원소 또는 6-원소로 구성된 링이고, 상기 (D)에 주어진 헤테로아릴 치환기의 의미중에서 선택된 0-2개의 치환기를 가질 수 있는 헤테로아릴(1-3C)알킬중에서 선택된다.
  2. 제1항에 있어서, X 및 Y가 각각 수소 및 할로중에서 선택되는 화합물.
  3. 제2항에 있어서, X와 Y는 각각 수소 및 클로로중에서 선택되고, R1이 (i) t-부틸, (ii) 2-메톡시페닐, 3-메톡시페닐, 및 일반식 RaRbNSO2(이때 Ra와 Rb는 각각 수소, 메틸 및 에틸중에서 선택된다)로 표시되는 아미노설포닐에 의해 2- 또는 3- 위치가 치환된 페닐, (iii) 티에닐, 푸릴, 및 2-위치가 (1-6C)알콕시, (1-6C)알킬티오, 또는 (1-6C)알킬설피닐에 의해 임의로 치환된 37피리딜로 이루어진 군중에서 선택되는 화합물.
  4. 제3항에 있어서, 1-((9S,10S)-2-클로로-9,10-디하이드로-9,10-메타노안트라센-9-일-메틸)-4-(1,1-대메틸에틸)피페리딘-4-올, 1-(9,10-디하이드로-9,10-메타노안트라센-9-일메틸)-4-(2-에틸설피닐-3-피리딜)피페리딘-4-올, 1-(9,10-디하이드로-9,10-메타노안트라센-9-일메틸)-4-(2-에틸티오-3-피리딜)피페리딘-4-올, 및 1-(2-클로로-9,10-디하이드로-9,10-메타노안트라센-9-일-메틸)-4-(2-메톡시-3-피리딜)피페리딘-4-올 중에서 선택되는 화합물.
  5. 제1항 내지 제4항중 어느 한 항에 있어서 정의한 일반식(Ⅰ)의 화합물과 약학적으로 허용가능한 부형제 또는 담체를 포함하는 약학 조성물.
  6. 하기 일반식(II)의 화합물.
    상기 식에서 X와 Y는 각각 수소, 할로, 및 (1-6C)알콕시중에서 선택된다.
  7. 하기 일반식(IIa)의 화합물.
    상기 식에서 X, Y 및 R1은 제1항에서 정의한 바와 같다.
  8. 하기 일반식(III)의 화합물.
    상기 식에서 X와 Y는 각각 수소, 할로, 및 (1-6C)알콕시중에서 선택되고, G는 G가 H 또는 OH일때 X와 Y는 둘다 H가 아니라는 조건하에, 클로로, OH 및 H중에서 선택된다.
  9. a) 하기 일반식(Ⅱ)로 표시되는 화합물을 비양성자성 용매중에서 일반식1Li로 표시되는 상응하는 화합물로 처리하거나, (b) 하기 일반식(IIa)의 상응하는 아미드를 적합한 환원제로 처리하거나, (c) G가 수소 원자인 하기 일반식(III)의 알데히드를 환원제의 존재하에 하기 일반식(IV)의 상응하는 피페리딘으로 처리하거나, (d) X와 Y중 어느 하나가 (1-6C)알콕시인 일반식(Ⅰ)의 화합물을 제조하고자 하는 경우에는, X 또는 Y가 히드록시인 상응하는 일반식(Ⅰ)의 화합물을 염기의 존재하에, 상응하는 (1-6C)알킬 할라이드로 처리하고, 그 후에 약학적으로 허용가능한 염을 제조하고자 하는 경우에는, 상기 화합물을 적합한 산과 함께 통상적인 방법으로 반응시키는 것을 특징으로 하는, 일반식(Ⅰ)의 화합물, 또는 그것의 약학적으로 허용가능한 염을 제조하는 방법.
    상기 식에서, X, Y 및 R1은 제1항에서 정의한 바와 같다.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019920014726A 1991-08-15 1992-08-14 메타노안트라센화합물 KR100245955B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9117639.6 1991-08-15
GB919117639A GB9117639D0 (en) 1991-08-15 1991-08-15 Therapeutic compounds

Publications (2)

Publication Number Publication Date
KR930004262A true KR930004262A (ko) 1993-03-22
KR100245955B1 KR100245955B1 (ko) 2000-04-01

Family

ID=10700033

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920014726A KR100245955B1 (ko) 1991-08-15 1992-08-14 메타노안트라센화합물

Country Status (25)

Country Link
EP (1) EP0533344B1 (ko)
JP (1) JP2889056B2 (ko)
KR (1) KR100245955B1 (ko)
AT (1) ATE144253T1 (ko)
AU (1) AU658905B2 (ko)
BG (1) BG61893B2 (ko)
CA (1) CA2076191A1 (ko)
CZ (1) CZ283848B6 (ko)
DE (1) DE69214588T2 (ko)
DK (1) DK0533344T3 (ko)
ES (1) ES2092646T3 (ko)
FI (1) FI102964B1 (ko)
GB (2) GB9117639D0 (ko)
GR (1) GR3021398T3 (ko)
HK (1) HK83697A (ko)
HU (2) HUT66625A (ko)
IE (1) IE922588A1 (ko)
IL (1) IL102807A (ko)
NO (1) NO301008B1 (ko)
NZ (1) NZ243955A (ko)
RU (1) RU2099328C1 (ko)
SG (1) SG48140A1 (ko)
SK (1) SK280356B6 (ko)
TW (1) TW221808B (ko)
ZA (1) ZA926148B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314250D0 (en) * 1993-07-09 1993-08-18 Zeneca Ltd Piperidinyl compounds
GB9216297D0 (en) * 1991-08-15 1992-09-16 Ici Plc Therapeutic agents
GB9216298D0 (en) * 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
CA2181759A1 (en) * 1995-07-26 1997-01-27 Mira A. Kanzelberger (thiophen-2-yl)-piperidin or tetrahydropyridin azabicyclocarboxamides
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1799664A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2007130075A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5911576B2 (ja) * 1975-07-07 1984-03-16 住友化学工業株式会社 新規なメタノ−アントラセン誘導体の製造法
US4358620A (en) * 1974-12-13 1982-11-09 Sumitomo Chemical Company, Limited 9-Formyl-9,10-dihydro-9,10-methanoanthracene
US4224344A (en) * 1974-12-13 1980-09-23 Sumitomo Chemical Company, Limited Organic tricyclic compounds
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
JPS5910654B2 (ja) * 1976-04-07 1984-03-10 住友化学工業株式会社 新規なメタノ−アントラセン誘導体

Also Published As

Publication number Publication date
KR100245955B1 (ko) 2000-04-01
NO923199L (no) 1993-02-16
AU2101492A (en) 1993-02-18
FI923663A (fi) 1993-02-16
ES2092646T3 (es) 1996-12-01
DK0533344T3 (ko) 1997-03-03
CA2076191A1 (en) 1993-02-16
SG48140A1 (en) 1998-04-17
TW221808B (ko) 1994-03-21
IE922588A1 (en) 1993-02-24
GB9216296D0 (en) 1992-09-16
HU9202643D0 (en) 1992-10-28
NO301008B1 (no) 1997-09-01
EP0533344A1 (en) 1993-03-24
NO923199D0 (no) 1992-08-14
BG61893B2 (bg) 1998-08-31
HU211661A9 (en) 1995-12-28
IL102807A0 (en) 1993-01-31
HK83697A (en) 1997-06-27
FI102964B (fi) 1999-03-31
AU658905B2 (en) 1995-05-04
NZ243955A (en) 1995-10-26
ZA926148B (en) 1993-04-28
GB9117639D0 (en) 1991-10-02
FI923663A0 (fi) 1992-08-14
GR3021398T3 (en) 1997-01-31
JP2889056B2 (ja) 1999-05-10
JPH05213872A (ja) 1993-08-24
IL102807A (en) 1998-08-16
CZ251992A3 (en) 1993-02-17
RU2099328C1 (ru) 1997-12-20
SK251992A3 (en) 1999-12-10
SK280356B6 (sk) 1999-12-10
EP0533344B1 (en) 1996-10-16
HUT66625A (en) 1994-12-28
FI102964B1 (fi) 1999-03-31
DE69214588D1 (de) 1996-11-21
DE69214588T2 (de) 1997-05-28
ATE144253T1 (de) 1996-11-15
CZ283848B6 (cs) 1998-06-17

Similar Documents

Publication Publication Date Title
KR930004262A (ko) 메타노안트라센 화합물
CA2423103A1 (en) N-acylsulfonamide apoptosis promoters
KR950704304A (ko) 이환식 헤테로환 함유 술폰아미드 및 술폰산 에스테르 유도체(bicyclic heterocyclic sulfonamide and sulfonic ester derivatives)
KR900014369A (ko) 신규의 퀴놀린 유도체, 이의 제조방법 및 이를 함유하는 향균제
KR950032180A (ko) 3-페닐피롤리딘 유도체
KR940000447A (ko) 티아졸의 분지쇄 알킬아미노유도체, 그의 제조방법 및 그를 함유하는 약제학적 조성물
DE69006984D1 (de) Thiazolidinedionederivate.
KR910021399A (ko) 치료제로서 유용한 3-아릴카르보닐-1h-인돌 및 그의 제조방법
CA2418656A1 (en) Proline derivatives and use thereof as drugs
KR900018073A (ko) 피페라진 화합물
FI950016A (fi) Heterosykliset yhdisteet lääkeaineena
KR940021063A (ko) 퀴놀론카르복실산 유도체, 이의 제조방법 및 용도
KR880009928A (ko) N-헤테로시클릭-n(4-피페리딜) 아미드와 이러한 화합물들을 사용하는 방법 및 제약학적 조성물
GB1014053A (en) 7-hydroxy-coumarin derivatives and process for their production
KR920021518A (ko) 피라진 유도체
KR920019781A (ko) 벤즈이미다졸류로부터 유도된 항진정 항히스타민제
KR920019746A (ko) 신규한 시클로헥실벤즈아미드 유도체, 그의 제조방법 및 약제로서의 용도
KR880006196A (ko) 알레르기 및 염증 치료제인 디하이드로피리딘
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
KR900016212A (ko) 피리딜티아졸리딘 카복스아미드 유도체 및 이의 중간체, 및 이들의 제조방법
HUT59124A (en) Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
KR880002828A (ko) 디하이드로피리딘 유도체 및 이것의 약학적 조성말
KR900001691A (ko) 피리다지논 유도체
KR930004234A (ko) 메타노안트라센 화합물
PT87025A (pt) Process for the preparation of imidazol derivatives and of pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920814

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19960619

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19970619

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970812

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920814

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19990325

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19990630

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19991029

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19991202

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19991203

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
G170 Re-publication after modification of scope of protection [patent]
LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20030909